CANCER RESEARCH JUST FLIPPED THE SCRIPT: MITOCHONDRIA + STEM CELLS + ORTHOMOLECULAR PROTOCOL The Journal of Orthomolecular Medicine just published a protocol that targets the mitochondrial-stem cell connection (MSCC) in cancer - combining orthomolecules, repurposed drugs, and dietary interventions into one hybrid approach. The protocol includes: · Intravenous Vitamin C: 1.5g/kg/day, 2–3x per week - established as non-toxic in cancer patients · Oral Vitamin D: Up to 50,000 IU/day until blood levels reach 80 ng/mL - then tapered to maintenance · Zinc: 1 mg/kg/day - with monthly monitoring to keep serum levels in the 80–120 µg/dL range · Ivermectin: Dosed by cancer grade - 0.5mg/kg (low) to 2mg/kg/day (high) · Benzimidazoles (Mebendazole/Fenbendazole): 200–1,500 mg/day depending on grade, with DON as a potential replacement or combo for metastatic cancers · Ketogenic Diet: 900–1,500 kcal/day, 60–80% fat, aiming for a Glucose Ketone Index (GKI) of 2.0 or below The scientific debate: This protocol sits at the crossroads of mainstream oncology and metabolic/metronomic approaches. The authors argue that "current treatments often fail because they do not address the mitochondrial and stem cell dynamics that drive tumour recurrence and resistance."